Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Jan;94(1):107-16.
doi: 10.1038/labinvest.2013.130. Epub 2013 Nov 11.

Programmed death ligand-1 expression in non-small cell lung cancer

Vamsidhar Velcheti  1 , Kurt A Schalper  2 , Daniel E Carvajal  2 , Valsamo K Anagnostou  3 , Konstantinos N Syrigos  4 , Mario Sznol  3 , Roy S Herbst  3 , Scott N Gettinger  3 , Lieping Chen  5 , David L Rimm  2
Affiliations

Programmed death ligand-1 expression in non-small cell lung cancer

Vamsidhar Velcheti et al. Lab Invest. 2014 Jan.

Abstract

Recent strategies targeting the interaction of the programmed cell death ligand-1 (PD-L1, B7-H1, CD274) with its receptor, PD-1, resulted in promising activity in early phase clinical trials. In this study, we used various antibodies and in situ mRNA hybridization to measure PD-L1 in non-small cell lung cancer (NSCLC) using a quantitative fluorescence (QIF) approach to determine the frequency of expression and prognostic value in two independent populations. A control tissue microarray (TMA) was constructed using PD-L1-transfected cells, normal human placenta and known PD-L1-positive NSCLC cases. Only one of four antibodies against PD-L1 (5H1) validated for specificity on this TMA. In situ PD-L1 mRNA using the RNAscope method was similarly validated. Two cohorts of NSCLC cases in TMAs including 340 cases from hospitals in Greece and 204 cases from Yale University were assessed. Tumors showed PD-L1 protein expression in 36% (Greek) and 25% (Yale) of the cases. PD-L1 expression was significantly associated with tumor-infiltrating lymphocytes in both cohorts. Patients with PD-L1 (both protein and mRNA) expression above the detection threshold showed statistically significant better outcome in both series (log-rank P=0.036 and P=0.027). Multivariate analysis showed that PD-L1 expression was significantly associated with better outcome independent of histology. Measurement of PD-L1 requires specific conditions and some commercial antibodies show lack of specificity. Expression of PD-L1 protein or mRNA is associated with better outcome. Further studies are required to determine the value of this marker in prognosis and prediction of response to treatments targeting this pathway.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.. PD-L1 protein and mRNA detection using chromogenic immunohistochemistry and quantitative fluorescence in cell lines and human tissues.
(a) Representative microphotographs showing PD-L1 protein expression using diaminobenzidine (brown chromogen, upper panels), immunofluorescence (red channel, middle panels) and fluorescent in situ PD-L1 mRNA (red channel, bottom panels) in human placenta, PD-L1 expressing Mel624 cells and parental Mel624 cells, × 400 magnification. Bar=60 μm. (b) PD-L1 protein and mRNA fluorescence measurements in several areas of FFPE preparations containing parental Mel624 (Mel624 (−)), PD-L1 Mel624 transfectants (Mel624 (+)) or human placenta. Each dot shows the fluorescence score within the mask in an independent field of view and scores are expressed as arbitrary units (AU). ***P<0.001, NS, not significant, (c) Representative fluorescence microphotographs of PD-L1 protein (left panels) staining in a positive (histospot 142) and negative NSCLC sample (histospot 274). Right panels show representative in situ PD-L1 mRNA staining in a positive (histospot 315) and a negative (histospot 70) NSCLC case. Nuclei were stained with DAPI. × 400 magnification. Bar=100 μm.
Figure 2.
Figure 2.. Distribution of PD-L1 protein and mRNA scores in the lung cohorts and assay reproducibility.
(a, b) Distribution of PD-L1 protein scores in cases from the Greek (a) and Yale (b) lung cohorts. The dashed line indicates the cutoff for positive/negative designation as described in the Materials and methods section. Inset shows reproducibility of PD-L1 protein measurements in two different cores (core 1 and core 2) obtained from the same case and paraffin block. R2 represents the linear regression coefficient and y represents the slope, (c, d) Distribution of PD-L1 mRNA scores in cases from the Greek (c) and Yale (d) lung cohorts. The dashed line indicates the cutoff for positive/negative designation as per negative control DapB scores. Inset shows relationship between PD-L1 protein and mRNA in both cohorts. R represents the Spearman correlation coefficient.
Figure 3.
Figure 3.. PD-L1 positivity and increased TILs is associated with better outcome in lung carcinomas.
(a, b) Kaplan-Meier graphical analysis of 5-year survival in patients with lung carcinomas in the Greek cohort (a) and the Yale University cohort (b) according to PD-L1 protein status. In both cohorts PD-L1-positive patients (black line) showed longer survival compared with negative cases (gray lines, log-rank P=0.0276 for Greek cohort and P=0.0369 for the Yale University cohort). (c, d) 5-Year survival in patients with lung carcinomas in the Greek cohort (c) and the Yale University cohort (d) according to PD-L1 mRNA status. PD-L1 mRNA-positive patients (black line) showed longer survival compared with negative cases (gray lines, log-rank P=0.012 for Greek cohort and P=0.003 for the Yale University cohort). (e, f) 5-Year survival in patients with lung carcinomas in the Greek cohort (e) and the Yale University cohort (f) according to the lymphocytic infiltrate. Cases with high lymphocytic infiltrate (black line, scores 2 and 3) showed longer survival compared with cases with low TILs (gray lines, scores 0 and 1) in both cohorts (log-rank P=0.0158 and 0.009, respectively). The number of cases in each group is indicated within the chart.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Detterbeck FC, Boffa DJ, Tanoue LT. The new lung cancer staging system. Chest 2009;136:260–271. - PubMed
    1. Petrelli NJ, Winer EP, Brahmer J et al. Clinical cancer advances 2009: major research advances in cancer treatment, prevention, and screening—a report from the American Society of Clinical Oncology. J Clin Oncol 2009;27:6052–6069. - PubMed
    1. Chen L Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat Rev Immunol 2004;4:336–347. - PubMed
    1. Sznol M, Chen L. Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer. Clin Cancer Res 2013;19:1021–1034. - PMC - PubMed
    1. Brahmer JR, Tykodi SS, Chow LQ et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. New Eng J Med 2012;366:2455–2465. - PMC - PubMed

Publication types

MeSH terms